Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.

BACKGROUND: One of the most common reasons for poor medication adherence and associated treatment failure of triple therapy is adverse drug effect (ADEs) of medications.
OBJECTIVE: Assessment of ADEs and associated factors during H. pylori eradication therapy.
METHOD: Consented H. pylori positive adult outpatients on standard triple therapy (proton pump inhibitor, amoxicillin and clarithromycin) were involved in this facility based follow up study from May 2016 to April 2018 at Bahir Dar city in Ethiopia. Pre-developed questionnaire and formats were used to collect sociodemographic, medical information, and patient practice data before, during, and after therapy. Bivariate and backward stepwise multivariate logistic regression was used to analyze data. P-value < 0.05 at 95%CI was considered as significant. RESULT: A total of 421 patients were involved in the study. Almost 80% of the patients were urban residents. Mean (±SD) age and body weight of patients were 30.63 (± 10.74) years and 56.79 (± 10.17) kg, respectively. ADE was reported from 26.1% of the patients and of all the reported ADEs, more than 85% was manifested with gastrointestinal symptoms which include gastrointestinal discomfort(39.1%), nausea (13.6%), constipation(12.7%), diarrhea(12.9%) and anorexia(10%). Determinants of self-reported ADEs among patients in the present study were body mass index above 25 (AOR: 2.55; 95%CI (1.21-5.38), p = 0.014), duration of acid-pepsin disorder more than 3weeks (AOR: 3.57; 95%CI (1.63-7.81), p = 0.001), pain feeling during long interval between meals (AOR: 2.14; 95%CI (1.19-3.84), p = 0.011), and residence in urban area (AOR: 1.95; 95% CI (1.04-3.67), p = 0.038).
CONCLUSION: Significant proportion of patients reported ADEs which commonly manifested with gastrointestinal symptoms. Consideration of patients' body mass index, duration of the disorder, period of the day when patients feel pain, and patients' area of residence could help to reduce ADEs experienced during H. pylori eradication therapy.

Introduction

Approximately two thirds of the world’s population is infected with Helicobacter pylori (H. pylori), making it the most widespread infection in the world[1]. Infection with H. pylori is a major cause of upper gastrointestinal diseases which includes peptic ulcer disease, chronic gastritis, gastric cancer, and mucosa-associated lymphoid tissue lymphoma[2-4].

According to 1996 Maastricht I consensus guideline recommendation, worldwide accepted H. pylori eradication therapy is always a multidrug regimen[5-7]. Within this multidrug regimen, there are different aspects of H. pylori eradication regimens that differ in the duration and the composition of drugs exist in the available guidelines and one of which is the standard triple therapy that consists of a combination of two antibiotics and an acid-suppressant drug[8,9].

Eradication of H. pylori infection in patients receiving medications can often be difficult because of different pushing factors. One of the commonly reported determinants of eradication failure is poor patient adherence to a multidrug regimen usually due to adverse drug effects of medications. Other determinants being the chosen regimen type and antibiotic resistance. Sociodemographic variations of patients, duration of peptic ulcer, cigarette smoking, genetics, and presence of other chronic diseases are also reported to affect eradication therapy[10-12]. Effort has been made to improve efficacy and safety of H. pylori eradication therapy through exploring new first-line treatments, investigating antibiotic resistance rates, evolution of the use of adjunctive therapies, and patient counselling and follow-up, however failure of H. pylori eradication therapy is the prevailing problem in clinical practice[13-20].

As it is true in many other pharmacotherapies, adverse drug effects (ADEs) are one the most common factors that affect the quality of the H. pylori eradication therapy. Although ADEs during H. pylori eradication therapy have been described as well tolerated, the therapy may be associated with significant adverse effects usually revealed with gastrointestinal symptoms that could bring about poor adherence of patients to medications leading to eradication failure[21-23]. Factors which might increase the risk of occurrence of ADEs include; extremes of age, gender, multiple drugs, disease state, past history of ADEs or allergy, genetic, factors, large doses and other patient sociodemographic and medical variables[10-12].

Previous studies including ours showed that adverse drug effect is one of the factors that influences H. pylori eradication rate in patients receiving standard triple therapy with proton pump inhibitor, amoxicillin and clarithromycin[24,25]. In Ethiopia, there are no studies done on the determinant factors for the occurrence of ADEs during H. pylori eradication therapy with the standard triple therapy. Thus the present study was amid to assess self-reported adverse drug effects and its associated factors during H. pylori eradication therapy in patients taking standard triple therapy.

Methods

Ethical issues

The study was approved by the Institutional Review Board of College of Medicine and Health Sciences, Bahir Dar University (Reference No: BCS/171/08). Permission was sought from the health institutions after presentation of the ethical approval. Written consent was obtained from each volunteer adult outpatients fulfilling inclusion criteria (S1 Text). All the drugs used in eradication therapy were approved by Food, Medicine, Healthcare Administration and Control Authority (FMHACA) of Ethiopia and the treatment protocol is as per national General Hospital Guideline. Patients were informed about the benefits and risks of the study as well as their full right to withdraw from the study at any time in point without jeopardizing the care. Moreover, privacy and confidentiality were maintained through anonymity and restricting data access.

Study design and setting

Facility based prospective follow up study was conducted from May 2016 to April 2018 in Bahir Dar, the capital city of Amhara Regional State, located 565 kilometers Northwest of Addis Ababa, the capital of Ethiopia. The study was conducted to assess adverse drug effects during H. pylori eradication therapy with standard triple therapy as part of the study that assess H. pylori eradication rate at two healthcare institutions namely Adinas General Hospital and Kidanemihret Higher Clinic both found in Bahir Dar city. The healthcare institutions were communicated officially through submitting letter of approval of the study protocol offered from Institutional Review Board of College of Medicine and Health Sciences at Bahir Dar University with reference No: BCS/171/08.

Patients on standard triple therapy

Of the total 526 consented H. pylori positive patients, this study was conducted on 421 patients who completed follow up (). All of them were adult outpatients (age ≥18 years) living in rural and urban settings and voluntarily agreed to give written consent. Those who were seriously sick or referred from other facilities as well as those who do not speak the local language (Amharic) were excluded from the study. Assessment of adverse drug effects experienced by patients were made following proton pump inhibitor (PPI)-based standard triple therapy with a regimen of PPI (omeprazole 40 mg or pantoprazole 40 mg, twice/day for 15 to 30 days), clarithromycin (500 mg), and amoxicillin (1000 mg), each twice/day for 10 or 14 days.

Fig 1

Flow chart depicting sequences of the study.

HCIs: healthcare institutions.

Data collection and management

Structured questionnaire developed from the literature was used to collect data in both the recruitment and the follow up period (S1 Table). The questionnaire was developed in English and translated into the local language Amharic and then back to English. Pre-test of the questionnaire was done on 5% of the sample size in another healthcare institution in the study area to ensure whether the questionnaire was able what it was intended to capture and modification of questions were made accordingly. Patients’ sociodemographic and medical information was collected during the first encounter. Data related to adverse drug effects, and also added-on homemade traditional remedies was collected during the follow up period on phone call and during their second encounter to check for eradication of H. pylori infection at the respective healthcare institutions (Fig 1). Both primary diagnosis as well as eradication of H. pylori after 4–6 weeks therapy was confirmed by a stool antigen test (S2 Table), which is recommended by both European and Japanese guidelines conducted according to the Manufacturer’s recommendation (SD BIOLINE H. pylori Ag, Standard Diagnostics, Inc. Korea)[26]. Data was collected by trained clinical pharmacists and nurses. Data accuracy and consistency was assured by the study team on daily basis. Besides collecting data through completion of structured questionnaire, stool sample was collected during the second encounter of patients to determine the success or failure of H. pylori eradication therapy.

Data analysis procedures

Data were entered and analyzed using SPSS statistical package version 21.0. Descriptive statistics such as percentages, means and standard deviations were used to describe data. Bivariate and multivariable logistic regressions were used to identify predictors of adverse drug effects of the standard triple-therapy. Those variables with a p-value in bivariate 0.25 were retained for multivariable logistic regression based on scientific recommendations[27]. The Hosmer-lemeshow test was checked to assess the model fattiness to conduct binary multiple logistic regression. All variables which fulfill Hosmer-Lemeshow were retained for multivariable logistic regression. Backward stepwise logistic regression model was used during multivariable logistic regression to control confounding effect. Odds ratio with 95% confidence intervals was calculated for each of the independent variables using P-value < 0.05 as the level of significance.

Results

Sociodemographic and medical characteristics of patients

A total of 421 patients were able to come back to the healthcare institution to confirm eradication success or failure and provide complete information related to adverse effects they had experienced during their eradication therapy. The mean age (SD) of patients was 30.63 (± 10.74) years, which ranges from 18–86. Nearly 90% of patients were under 45 years old. The mean weight of patients was 56.71 (±10.19) kg. The mean body mass index of all patients was 21.09 (±4.16).

As shown in Table 1, two-third of the patients were females and majority (80%) of the patients were urban dwellers. Close to two-third (63.4%) of them were married and a sizable proportion (42%) of them attended college education or above. Occupation wise, around 38% of the patients were employees of government and private sectors with monthly paid salary and around 62% of patients were engaged in their own income generating activities that include housewives, merchants, farmers, students, and daily laborers. Majority (86%) of the patients were followers of Ethiopian Orthodox Church.

Table 1

Sociodemographic and medical information of patients participated in the study of adverse drug effects of standard triple therapy in selected healthcare institutions at Bahir Dar City Administration, May 2016 to April 2018.

(N = 421).

Variable and their categories	Frequency and percentage	Self-report on ADEs		Self-reported ADEs in %
		Yes (n = 110)	No (n = 311)
Sex
Female	276(65.6)	80	196	29.0
Male	145(34.4)	30	115	20.7
Body mass index
<20	151(35.9)	35	116	23.2
20–25	222(52.7)	56	166	25.2
>25	48(11.4)	19	29	39.6
Age in years
18–24	125(29.7)	33	92	26.4
25–34	172(40.9)	40	132	23.3
35–44	75(17.8)	23	52	30.7
≥ 45	49(11.6)	14	35	28.6
Residence
Urban	336(79.8)	95	241	28.3
Rural	85(20.2)	15	70	17.5
Patents' Zonal address
Bahir Dar city	169(40.1)	45	124	26.6
West Gojjam	96(22.8)	22	74	22.9
South Gondar	62(14.7)	15	47	24.2
Awi zone	52(12.4)	16	36	30.1
Others zones	42(10.0)	12	30	28.6
Marital status
Single	145(34.5)	34	111	23.4
Married	267(63.4)	73	194	27.3
Divorced/Widowed	9(2.1)	3	6	33.3
Occupation
Employee	159 (37.8)	46	113	28.9
Non-employee	262(62.2)	64	198	24.4
Educational status
Grade 1–8 and below	141(33.5)	35	106	24.8
Grade 9–12	104(24.7)	30	74	28.8
College and above	176(41.8)	45	131	25.6
Time duration of the disorder
≤ 3weeks	110(15.9)	9	101	8.2
>3weeks	354(84.1)	101	253	28.5
Presence of other disease(s)
Yes	108(25.6)	25	83	23.1
No	313(74.3)	85	228	27.2
Self-reported alcohol intake
Yes	237(56.3)	52	185	21.9
No	184(43.7)	58	126	31.5
Pain feeling period in the day
After meal	217(51.5)	46	171	21.2
Persistent in the day	122(29.0)	35	87	28.7
Long interval b/n meals	82(19.5)	29	53	35.4
Use of Flaxseed or Fenugreek
Yes	135(32.1)	35	100	25.9
No	286(67.9)	75	211	26.2
Triple therapy regimen durations
10 day	279(66.3)	79	200	28.3
14 day	142(33.7)	31	111	21.8
Self-reported regimen completion
Yes	397(94.3)	100	297	25.2
No	24(5.7)	10	14	41.7
Disease symptom resolution
Yes	355(84.3)	91	264	25.6
No	66(15.7)	19	47	28.8

As summarized in Table 1, almost 85% of them said that they had been living with symptoms of acid-pepsin disorder for more than 3 weeks. Almost half of the patients responded that they feel pain after meal, while 29% reported that the pain feeling persists throughout the day. About a fourth (25.6%) of the patients have responded the presence of other chronic diseases and patients response on alcohol intake before receiving triple therapy was 56.3%. One-quarter of patients reported presence of other chronic diseases of which renal impairment was the highest representing 45.4% of the cases. Almost a third (32.1%) of patients reported that they had taken diets traditionally believed to have healing effect on gastritis and peptic ulcer disease like Fenugreek and Flaxseed together with the triple therapy. Nearly two-third (66.3%) of patients received standard triple therapy for 10 days duration and the remaining for 14 days. The overall H. pylori eradication rate (success of the therapy) was 90% which was a bit lower than self-reported regimen completion 94.3%. However percentage of patients who reported symptom resolution of the disorder was 84.3%.

As shown in Table 1 the contribution of females and males to the reported ADEs of patients was 29.0% and 20.7% respectively. Similarly the contribution of some variable among others were; urban and rural (28.3% vs. 17.5%), disorder duration up to 3 and above three weeks (8.2% vs. 28.5%), history of alcohol intake and no intake (21.9% vs. 31.5%), 10 days and 14 days regimen (28.1% vs. 21.8%), used and not used Fenugreek or Flaxseed (25.9% vs.26.2%), symptom resolved and unresolved (25.6 vs. 28.8%) and eradication success and failure (23.7% vs. 47.6%).

As indicated in Table 2, almost a fourth (26.1%) of the patients responded that they had experienced one or more adverse drug effects while taking medications. Of the overall reported ADEs, more than 85% was gastrointestinal type which includes gastrointestinal discomfort(39.1%), nausea(13.6%), constipation(12.7%), diarrhea(12.9%) and anorexia(10%).

Table 2

Frequency and percentage of self-reported adverse drug effects of patients received standard triple therapy in selected healthcare institutions at Bahir Dar city, May 2016 to April 2018.

(N = 421).

Self-reported ADEs	Relative Frequency and percentage of self-reported ADEs (n = 110)	Overall percentage of self-reported ADEs (N = 421)
GI discomfort	43(39.1)	10.2
Nausea	15(13.6)	3.6
Headache and drowsiness	15(13.6)	3.6
Constipation	14(12.7)	3.3
Diarrhea	12(10.9)	2.8
Anorexia	11(10.0)	2.6
Over all	110(100)	26.1

Factors associated with adverse drug effects

Bivariate and multiple logistic regression analysis is shown in Table 3. On bivariate logistic regression analysis, the following variables were significantly associated with self-reported ADEs on receiving standard triple therapy: body mass index >25 (COR: 2.17 95%CI (1.01–4.33), p = 0.028); urban area residence (COR: 1.84 95%CI (1.00–3.37), p = 0.049), disease duration more than 3 weeks (COR: 2.57 95%CI (1.23–5.39), p = 0.012), history of pain feeling during long interval between meals (COR: 2.03 95%CI (1.16–3.56), p = 0.013), and history of no alcohol intake (COR: 1.24 95%CI (0.74–2.07), p = 0.027).

Table 3

Binary and multiple logistic regression analysis for factors associated with self-reported adverse drug effects on receiving standard triple therapy in selected healthcare institutions at Bahir Dar city, May 2016 to April 2018.

(N = 421).

Variable Categories	ADEs		Crude odds ratio*	Adjusted odds ratio**
	Yes	No
Sex
Female	80	196	1.57(0.97–2.52)g
Male	30	115	1.00
Body mass index
<20	35	116	1.00
20–25	56	166	1.12(0.69–1.82)
>25	19	29	2.17(1.01–4.33)a	2.55(1.21–5.34)1
Age in years
18–24	33	92	0.90(0.41–1.99)
25–34	40	132	0.76(0.42–1.54)
35–44	23	52	1.11(0.50–2.43)
≥45	14	35	1.00
Residence				1.95(1.04–3.67)2
Urban	95	24	1.84(1.00–3.37)b
Rural	15	170	1.00
Zonal address
Bahir Dar city	45	124	1.00
West Gojjam	22	74	0.82(0.46–1.47)
South Gondar	15	47	0.88(0.45–1.73)
Awi zone	16	36	1.23(0.62–2.42)
Other zones	12	30	1.10(0.52–2.34)
Marital status
Single	34	111	1.00
Married	73	194	1.23(0.76–1.96)
Divorced/Widowed	3	6	1.63(0.39–6.90)
Occupation	46
Employee	64	113	1.26(0.81–1.96)
Non-employee		198	1.00
Educational status
Grade 1–8 and below	35	106	0.96(0.62–1.73)
Grade 9–12	30	74	1.18(0.49–1.46)
College and above	45	131	1.00
Time duration of the disorder
≤ 3weeks	9	101	1.00
>3weeks	101	253	2.57(1.23–5.39)c	3.57(1.63–7.81)3
Pain feeling period in the day
After meal	46	171	1.00
Persistent in the day	35	87	1.36(0.90–2.48)
Long interval b/n meals	29	53	2.03(1.16–3.56)d	2.14(1.19–3.84)4
Presence of other disease(s)
Yes	25	83	0.81(0.48–1.35)
No	85	228	1.00
Self-reported alcohol intake
Yes	52	185	1.00
No	58	126	1.64(1.06–2.54)e
Regimen durations
10day	79	200	1.00
14day	31	111	0.71(0.44–1.14)f
Use of Flaxseed or Fenugreek
Yes	35	100	1.00
No	75	211	1.02(0.64–1.61)
Self-reported regimen completion
Yes	100	297	1.00
No	10	14	2.12(0.91–4.93)f
Disease symptom resolution
Yes	91	264	1.00
No	19	47	1.17(0.65–2.10)

*P values for binary logistic regression:

a = 0.028

b = 0.049

c = 0.012

d = 0.013

e = 0.027

f<0.25 but not significant.

**P values for multivariate logistic regression

1 = 0.014

2 = 0.038

3 = 0.001

4 = 0.011

As indicated in Table 3 above, on multivariable binary logistic regression model analysis; body mass index more than 25, duration of acid-pepsin disorder more than 3 weeks, history of pain feeling during long interval between meals, and urban area residence were significantly contributing factors for self-reported ADEs in patients on standard triple therapy. Patients with body mass index more than 25 were 2.55 (AOR: 2.55; 95%CI (1.21–5.38), p = 0.014) times more likely to report ADEs on receiving standard triple therapy compared to patients with body mass index less than 20. Patients with duration of acid-pepsin disorder more than 3weeks were 3.57 (AOR: 3.57; 95%CI (1.63–7.61), p = 0.001) times more likely to report ADEs compared with patients who stayed up to 3weeks. Patients with history of pain feeling during long interval between meals were 2.14 (AOR: 2.14; 95%CI (1.19–3.84), p = 0.011) times more likely to report ADEs compared to patients who feel pain after meal. Patients living in urban areas were 1.95 (AOR: 1.95; 95% CI (1.04–3.67), p = 0.038) times more likely to report ADEs compared to patients whose eradication therapy was successful.

Discussion

Eradication therapy of H. pylori infections have proven to be difficult for different reasons. Assessment of patient and pathogen related factors could insight ways of improving treatment outcome. We evaluated self-reported ADEs that occurred during standard triple therapy and associated risk conditions of the patient that could bring about occurrence of ADEs in H. pylori eradication therapy. Many factors affect the occurrence of ADEs during H. pylori eradication therapy regimens[28]. Understanding the different effects of these factors on ADEs enables healthcare professionals to choose most appropriate medications and give the best advice to patients[23,29].

Of 421 patients who were able to comeback for after 4–6 weeks completion of eradication therapy 110 (26.13%) reported their experience of one or more types of ADEs. These adverse effects were mild, with no documented serious adverse events. The most commonly reported ADEs were manifested with gastrointestinal symptoms which include; gastrointestinal discomfort, nausea, vomiting, diarrhea and constipation. Similar finding of gastrointestinal dominance have been reported in other studies elsewhere[23,30,31]. Self-reported ADEs in the present study was comparable 19%[32], higher than 10% -18% [33-36] and lower than 36%-76% [37-40] reported previously. The variability could be due to different factors such as duration of triple therapy, socio-demographic differences of patients, duration and severity of the disease, pharmacogenetic variability among patients, and drug combinations and possible interactions among these factors.

Predictors of self-reported ADEs of H. pylori eradication standard triple therapy identified in this study were female sex, urban area of residence, patient history of more than three months duration with the disease, pain feeling during long interval between meals, and residence in urban areas.

Body mass index higher than 25 was predictor of self-reported ADEs during triple therapy which could be due to more stomach distension in obese patients [41] directly linked to gastrointestinal symptoms and/or slow gastric emptying in obese patients[42] facilitating significant alteration of gastrointestinal microflora which can be responsible for reported gastrointestinal ADEs. On the other hand it could be also possible to associate higher ADEs in obese patients with slow elimination of drugs specially clarithromycin that has high tissue concentrations as reported previously ([43,44]. Negative impact of higher body mass index on H. pylori eradication therapy has been reported[45] which might be linked with ADEs that reduce drug intake. In addition higher H. pylori infection rate has been reported[1,46] in obese people. To have a better understanding of H. pylori infection and its eradication therapy in relation to body mass index needs further studies as it was also suggested elsewhere [47].

Patients who have been feeling pain during long interval between meals were more likely to report ADEs of medications compared with those who feel pain after meal. This could be due to reporting of disease symptoms as medication adverse effects because both conditions produce upper abdominal pain or discomfort. Similarly H. pylori positive patients with history of acid-pepsin disorder more than 3 weeks were more likely to report ADEs compared with those less than 3 weeks. Lower reporting of ADEs in patients with active ulcer could be relative tolerance of drugs’ effects compared with more severe pain of the active ulcer and more reporting of ADEs during inactive ulcer could also be relative severity of ADEs than inactive ulcer induced pain. Although the same study is not found, study conducted on eradication of H. pylori in patients with active and inactive ulcers reported better rate of eradication in patients with active ulcer[48]. Parallel to this higher adherence rate has been found among the patients with acute conditions compared to those with chronic diseases[49]. Although there was no similar study that reported the effect of residence on H. pylori eradication with standard triple therapy some controversial reports exist in previously reported therapies[50-52]. The difference could be due to better awareness of urban patients to pay attention and reporting adverse drug effects than rural counter parts possibly associated with their differences in several aspects.

The other variable which was significant in predicting self-reported ADEs on bivariate but not on multivariate logistic regression includes history of free from self-reported alcohol intake. Patients who responded no alcohol intake prior to therapy were more likely to report ADEs (p value = 0.027) than those reported alcohol intake. This could be due to fast elimination of drugs in patients taking alcohol because of its documented inducer effect[53,54].

There was a tendency of weak association female sex and self- reported ADEs during H. pylori eradication with triple therapy in this study. Although there was no similar study that reported female sex as a risk factor in development of ADEs during triple therapy, in many other therapies reviewers indicated more ADEs in females that could be due to anatomical and physiological differences such as lower bodyweight and organ size, more body fat, different gastric motility and lower glomerular filtration rate or more attentiveness to recall and report physical illness or symptom perceptions[12,55,56]. Although patients were given the same dose with the common name adult, the mean weight of females and males was 55.2(SD = 10.1) and 59.6 (SD = 9.7) respectively in this study.

There was no difference in self-reported adverse drug effects between 10 days and 14 days triple therapy regimen in this study which is similar to reported study elsewhere[10,33,57]. Following eradication therapy 84.3% of patients reported disease symptom resolution which was a bit lower than reported 91%[57]. Self-reported regimen completion was 94.3% in this study which was comparable with 95.7[58] and a bit lower than 99.8% reported elsewhere[59] and it has no significant influence on self-reported adverse effects. The response of patients showed that 84.3% of patients achieved complete resolution of acid-pepsin disorder symptoms. This value was lower than the 90% H. pylori eradication rate which could suggest that H. pylori eradication may not bring about complete symptom resolution. On the contrary acid-pepsin disorder symptoms may be resolved in patients with eradication failure.

Limitation

Self- reported ADEs in this study could be different from the actual or reported values due to cultural and awareness differences of patients in developing and developed countries.

Conclusion

Significant proportion of patients on standard triple therapy to eradicate H. pylori reported ADEs mostly manifested with gastrointestinal symptoms. Reduction of these ADEs of medications should take into account of patients’ body mass index, duration of the disorder, period of the day when patients feel pain and patients’ area of residence which could help to improve H. pylori eradication. Use of traditional homemade remedies prepared from Flaxseed or Fenugreek lacks to reduce the risk of ADEs during standard triple therapy and thus the healthcare practice shall not be influenced until this traditional practice will to be proven otherwise.

Raw dataset.

(SAV)

Click here for additional data file.

Predeveloped structured questionnaire in both English and Amharic versions.

(PDF)

Click here for additional data file.

Format for H. pylori stool antigen test (SAT) data collection.

(PDF)

Click here for additional data file.

Written consent form.

(PDF)

Click here for additional data file.

24 Oct 2019

PONE-D-19-23464

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: prospective follow up study

PLOS ONE

Dear Dr Gebeyehu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Dec 08 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Yan Li

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

4. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information."

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study aimed to know the associated factors about the adverse drug effects during Helicobacter pylori eradication. This report is interesting and can be helpful to the clinicians for increasing compliance of H. pylori eradication regimen. However, I think that some of the results and conclusions of this paper seem to be incorrect.

Comments

1. Authors analyzed the factors associated with self-reported ADE using binary and multiple logistic regression. The results showed that failure of eradication therapy was one of the associated factors for ADE and, based on the results, the authors argued that failure of eradication therapy is one of predictors of ADEs. The factors which can affect ADEs are what we can know before treatment, therefore, treatment failure can not be included. If authors want to know that ADEs can affect treatment failure, you should analyze the associated factors for success of H. pylori eradication including ADEs as variable.

2. It will be better to make flow chart as Figure 1 for easier understanding of study sequences.

Reviewer #2: In this interesting manuscript, the authors described a prospective follow up study"Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy"

the manuscript is sound and in the good writing, I don't have any further comments on this paper, recommend to be accepted .

Thank you for invitation,

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

7 Nov 2019

We are happy on your decision of "resivion required" on our manuscript since it has given us a chance to imptove the scientific acceptance of the article. We believe that we have corrected the manuscript according to you comments. The detail of our response to reviewers is uploaded with the document file called Response to Reviewers.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

8 Nov 2019

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: prospective follow up study

PONE-D-19-23464R1

Dear Dr. Gebeyehu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Yan Li

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

15 Nov 2019

PONE-D-19-23464R1

Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: prospective follow up study

Dear Dr. Gebeyehu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yan Li

Academic Editor

PLOS ONE